SCHEMBL7629465

SCHEMBL7629465

Cc1nc(Cn2c(N3CCCN(C(=O)OC(C)(C)C)CC3)nc3ccccc32)cs1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
NPSR1 Q6W5P4 2/20 0.46
CKS1B P61024 1/20 0.44
SKP1 P63208 1/20 0.44
SKP2 Q13309 1/20 0.44
OPRM1 P35372 1/20 0.43
OPRD1 P41143 1/20 0.43
OGFRL1 Q5TC84 1/20 0.43
TSHR P16473 2/20 0.43
GBA1 P04062 1/20 0.42
PDE10A Q9Y233 1/20 0.41
POLB P06746 1/20 0.41
LMNA P02545 3/20 0.40
MAPT P10636 2/20 0.40
ACKR3 P25106 1/20 0.40
KCNH2 Q12809 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7628660 0.83 ALDH1A1 (0.56) ALDH1A1NPSR1CKS1BSKP1SKP2
SCHEMBL6595306 0.82 ALDH1A1 (0.57) ALDH1A1NPSR1CKS1BSKP1SKP2
SCHEMBL6595962 0.81 HTR3A (0.56) KCNH2
SCHEMBL7626255 0.81 ALDH1A1 (0.51) ALDH1A1NPSR1CKS1BSKP1SKP2
SCHEMBL6599123 0.81 ALDH1A1 (0.48) ALDH1A1NPSR1CKS1BSKP1SKP2
SCHEMBL7627768 0.80 ALDH1A1 (0.55) ALDH1A1NPSR1OPRM1OPRD1OGFRL1
SCHEMBL7620342 0.80 OPRM1 (0.51) ALDH1A1NPSR1CKS1BSKP1SKP2
SCHEMBL6596284 0.80 HTR3A (0.53) ALDH1A1NPSR1CKS1BSKP1SKP2
SCHEMBL6592173 0.79 ALDH1A1 (0.59) ALDH1A1NPSR1POLB
SCHEMBL7487632 0.79 ALDH1A1 (0.53) ALDH1A1NPSR1CKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6423704-B2 CROHN'S DISEAS, ANTIULCER AGENTS, ASTHMA, EMESIS AVENTIS PHARMACEUTICALS INC. 2002-07-23 US disclosed
US-20010034343-A1 Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases AVENTIS PHARMACEUTICALS INC. 2001-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034343-A1 Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases HRH4, HRH2, HRH1 ALDH1A1 953/4885NPSR1 102/4885CKS1B 853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.